
Chinese General Practice ›› 2021, Vol. 24 ›› Issue (33): 4177-4184.DOI: 10.12114/j.issn.1007-9572.2021.02.001
Special Issue: 肿瘤最新文章合辑
• Monographic Research • Previous Articles Next Articles
Published:2021-11-20
Online:2021-11-20
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.02.001
| [1]SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.DOI:10.3322/caac.21660. [2]SIEGEL R L,TORRE L A,SOERJOMATARAM I,et al.Global patterns and trends in colorectal cancer incidence in young adults[J].Gut,2019,68(12):2179-2185.DOI:10.1136/gutjnl-2019-319511. [3]LUI R N,TSOI K K F,HO J M W,et al.Global increasing incidence of young-onset colorectal cancer across 5 continents:a joinpoint regression analysis of 1,922,167 cases[J].Cancer Epidemiol Biomarkers Prev,2019,28(8):1275-1282.DOI:10.1158/1055-9965.EPI-18-1111. [4]LOOMANS-KROPP H A,UMAR A.Increasing incidence of colorectal cancer in young adults[J].J Cancer Epidemiol,2019,2019:1-9.DOI:10.1155/2019/9841295. [5]VUIK F E,NIEUWENBURG S A,BARDOU M,et al.Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years[J].Gut,2019,68(10):1820-1826.DOI:10.1136/gutjnl-2018-317592. [6]吴春晓,顾凯,龚杨明,等.2015年中国结直肠癌发病和死亡情况分析[J].中国癌症杂志,2020,30(4):241-245.DOI:10.19401/j.cnki.1007-3639.2020.04.001. WU C X,GU K,GONG Y M,et al.Analysis of incidence and mortality of colorectal cancer in China,2015[J].China Oncol,2020,30(4):241-245.DOI:10.19401/j.cnki.1007-3639.2020.04.001. [7]ZHANG L,CAO F,ZHANG G Y,et al.Trends in and predictions of colorectal cancer incidence and mortality in China from 1990 to 2025[J].Front Oncol,2019,9:98.DOI:10.3389/fonc.2019.00098. [8]GENEVE N,KAIRYS D,BEAN B,et al.Colorectal cancer screening[J].Prim Care,2019,46(1):135-148.DOI:10.1016/j.pop.2018.11.001. [9]KAHI C J.Reviewing the evidence that polypectomy prevents cancer[J].Gastrointest Endosc Clin N Am,2019,29(4):577-585.DOI:10.1016/j.giec.2019.05.001. [10]SHARMA T.Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults[J].Public Health,2020,182:70-76.DOI:10.1016/j.puhe.2020.01.021. [11]PROVENZALE D,NESS R M,LLOR X,et al.NCCN guidelines insights:colorectal cancer screening,version 2.2020[J].J Natl Compr Canc Netw,2020,18(10):1312-1320.DOI:10.6004/jnccn.2020.0048. [12]李鹏,王拥军,陈光勇,等.中国早期结直肠癌及癌前病变筛查与诊治共识[J].中国实用内科杂志,2015,35(3):211-227. DOI:10.7504/nk2015020301. [13]YANG Y,WANG H Y,CHEN Y K,et al.Current status of surgical treatment of rectal cancer in China[J].Chin Med J (Engl),2020,133(22):2703-2711.DOI:10.1097/CM9.0000000000001076. [14]WOLF A M D,FONTHAM E T H,CHURCH T R,et al.Colorectal cancer screening for average-risk adults:2018 guideline update from the American Cancer Society[J].CA Cancer J Clin,2018,68(4):250-281.DOI:10.3322/caac.21457. [15]LEDDIN D,LIEBERMAN D A,TSE F,et al.Clinical practice guideline on screening for colorectal cancer in individuals with a family history of nonhereditary colorectal cancer or adenoma:the Canadian association of gastroenterology Banff consensus[J].Gastroenterology,2018,155(5):1325-1347.e3.DOI:10.1053/j.gastro.2018.08.017. [16]BAGLIONI P.The IARC perspective on colorectal cancer screening[J].N Engl J Med,2018,379(3):301.DOI:10.1056/NEJMc1807173. [17]BARICHELLO S,DENG L,ISMOND K P,et al.Comparative effectiveness and cost-effectiveness analysis of a urine metabolomics test vs. alternative colorectal cancer screening strategies[J].Int J Colorectal Dis,2019,34(11):1953-1962.DOI:10.1007/s00384-019-03419-7. [18]RAN T,CHENG C Y,MISSELWITZ B,et al.Cost-effectiveness of colorectal cancer screening strategies——a systematic review[J].Clin Gastroenterol Hepatol,2019,17(10):1969-1981.e15.DOI:10.1016/j.cgh.2019.01.014. [19]CALDERWOOD A H.Importance of age-specific insurer perspective on lifetime cost effectiveness of colorectal cancer screening[J].Am J Gastroenterol,2018,113(12):1754-1756.DOI:10.1038/s41395-018-0386-z. [20]LEW J B,ST JOHN D J B,MACRAE F A,et al.Evaluation of the benefits,harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia[J].Int J Cancer,2018,143(2):269-282.DOI:10.1002/ijc.31314. [21]JAHN B,SROCZYNSKI G,BUNDO M,et al.Effectiveness,benefit harm and cost effectiveness of colorectal cancer screening in Austria[J].BMC Gastroenterol,2019,19(1):209.DOI:10.1186/s12876-019-1121-y. [22]TANDAY S.Updated Canadian colorectal cancer screening guidelines[J].Lancet Oncol,2016,17(4):e137.DOI:10.1016/S1470-2045(16)00139-X. [23]REX D K,BOLAND C R,DOMINITZ J A,et al.Colorectal cancer screening:recommendations for physicians and patients from the US multi-society task force on colorectal cancer[J].Gastroenterology,2017,153(1):307-323.DOI:10.1053/j.gastro.2017.05.013. [24]HADJILIADIS D,KHORUTS A,ZAUBER A G,et al.Cystic fibrosis colorectal cancer screening consensus recommendations[J].Gastroenterology,2018,154(3):736-745.e14.DOI:10.1053/j.gastro.2017.12.012. [25]YEE J,KIM D H,ROSEN M P,et al.ACR Appropriateness Criteria colorectal cancer screening[J].J Am Coll Radiol,2014,11(6):543-551.DOI:10.1016/j.jacr.2014.02.006. [26]LOPES G,STERN M C,TEMIN S,et al.Early detection for colorectal cancer:ASCO resource-stratified guideline[J].J Glob Oncol,2019,5:1-22.DOI:10.1200/JGO.18.00213. [27]MONAHAN K J,BRADSHAW N,DOLWANI S,et al.Guidelines for the management of hereditary colorectal cancer from the British society of gastroenterology (BSG)/association of coloproctology of great Britain and Ireland (ACPGBI)/united kingdom cancer genetics group (UKCGG)[J].Gut,2020,69(3):411-444.DOI:10.1136/gutjnl-2019-319915. [28]US Preventive Services Task Force,BIBBINS-DOMINGO K,GROSSMAN D C,et al.Screening for colorectal cancer:US preventive services task force recommendation statement[J].JAMA,2016,315(23):2564-2575.DOI:10.1001/jama.2016.5989. [29]The Lancet Gastroenterology Hepatology.USPSTF recommends expansion of colorectal cancer screening[J].Lancet Gastroenterol Hepatol,2021,6(1):1.DOI:10.1016/S2468-1253(20)30361-7. [30]SILVA-ILLANES N,ESPINOZA M.Critical analysis of Markov models used for the economic evaluation of colorectal cancer screening:a systematic review[J].Value Health,2018,21(7):858-873.DOI:10.1016/j.jval.2017.11.010. [31]柏愚,杨帆,马丹,等.中国早期结直肠癌筛查及内镜诊治指南(2014年,北京)[J].胃肠病学,2015,20(6):345-365. DOI:10.3969/j.issn.1008-7125.2015.06.006. [32]郑树,张苏展,蔡三军,等.中国结直肠肿瘤早诊筛查策略专家共识[J].中华胃肠外科杂志,2018,21(10):1081-1086.DOI:10.3760/cma.j.issn.1671-0274.2018.10.001. ZHENG S,ZHANG S Z,CAI S J,et al.Expert consensus on early diagnosis and screening strategies for colorectal tumors in China [J].Chinese Journal of Gastrointestinal Surgery,2018,21(10):1081-1086.DOI:10.3760/cma.j.issn.1671-0274.2018.10.001. [33]国家消化系统疾病临床医学研究中心(上海),国家消化道早癌防治中心联盟,中华医学会消化内镜学分会,等.中国早期结直肠癌筛查流程专家共识意见(2019,上海)[J].中华医学杂志,2019,99(38):2961-2970.DOI:10.3760/cma.j.issn.0376-2491.2019.38.001. [34]国家癌症中心中国结直肠癌筛查与早诊早治指南制定专家组.中国结直肠癌筛查与早诊早治指南(2020,北京)[J].中华肿瘤杂志,2021,43(1):16-38.DOI:10.3760/cma.j.cn112152-20210105-00010. National Cancer Center,China,Expert Group of the Development of China Guideline for the Screening,Early Detection and Early Treatment of Colorectal Cancer.China guideline for the screening,early detection and early treatment of colorectal cancer(2020,Beijing)[J].Chin J Oncol,2021,43(1):16-38.DOI:10.3760/cma.j.cn112152-20210105-00010. [35]CENIN D R,NABER S K,DE WEERDT A C,et al.Cost-effectiveness of personalized screening for colorectal cancer based on polygenic risk and family history[J].Cancer Epidemiol Biomarkers Prev,2020,29(1):10-21.DOI:10.1158/1055-9965.EPI-18-1123. [36]SUBRAMANIAN S,BOBASHEV G,MORRIS R J,et al.Personalized medicine for prevention:can risk stratified screening decrease colorectal cancer mortality at an acceptable cost?[J].Cancer Causes Control,2017,28(4):299-308.DOI:10.1007/s10552-017-0864-4. [37]NABER S K,KUNDU,KUNTZ K M,et al.Cost-effectiveness of risk-stratified colorectal cancer screening based on polygenic risk:current status and future potential[J].JNCI Cancer Spectr,2020,4(1):pkz086.DOI:10.1093/jncics/pkz086. [38]KNUDSEN A B,ZAUBER A G,RUTTER C M,et al.Estimation of benefits,burden,and harms of colorectal cancer screening strategies:modeling study for the US preventive services task force[J].JAMA,2016,315(23):2595-2609.DOI:10.1001/jama.2016.6828. [39]LADABAUM U,MANNALITHARA A,MEESTER R G S,et al.Cost-effectiveness and national effects of initiating colorectal cancer screening for average-risk persons at age 45 years instead of 50 years[J].Gastroenterology,2019,157(1):137-148.DOI:10.1053/j.gastro.2019.03.023. [40]ROBERTSON D J,LADABAUM U.Opportunities and challenges in moving from current guidelines to personalized colorectal cancer screening[J].Gastroenterology,2019,156(4):904-917.DOI:10.1053/j.gastro.2018.12.012. [41]LIEBERMAN D.Race,gender,and colorectal cancer screening[J].Am J Gastroenterol,2005,100(12):2756-2758.DOI:10.1111/j.1572-0241.2005.00352.x. [42]MEESTER R G S,PETERSE E F P,KNUDSEN A B,et al.Optimizing colorectal cancer screening by race and sex:Microsimulation analysis Ⅱ to inform the American Cancer Society colorectal cancer screening guideline[J].Cancer,2018,124(14):2974-2985.DOI:10.1002/cncr.31542. [43]OHRI A,ROBINSON A,LIU B,et al.Updated assessment of colorectal cancer incidence in the U.S.by age,sex,and race/ethnicity[J].Dig Dis Sci,2020,65(6):1838-1849.DOI:10.1007/s10620-019-05913-y. [44]SCHOENFELD P.Quality in colorectal cancer screening with colonoscopy[J].Gastrointest Endosc Clin N Am,2020,30(3):541-551.DOI:10.1016/j.giec.2020.02.014. [45]NABER S K,KUNTZ K M,HENRIKSON N B,et al.Cost effectiveness of age-specific screening intervals for people with family histories of colorectal cancer[J].Gastroenterology,2018,154(1):105-116.e20.DOI:10.1053/j.gastro.2017.09.021. [46]KAMINSKI M F,ROBERTSON D J,SENORE C,et al.Optimizing the quality of colorectal cancer screening worldwide[J].Gastroenterology,2020,158(2):404-417.DOI:10.1053/j.gastro.2019.11.026. [47]DE KLERK C M,GUPTA S,DEKKER E,et al.Socioeconomic and ethnic inequities within organised colorectal cancer screening programmes worldwide[J].Gut,2018,67(4):679-687.DOI:10.1136/gutjnl-2016-313311. [48]CHEN H D,LI N,REN J S,et al.Participation and yield of a population-based colorectal cancer screening programme in China[J].Gut,2019,68(8):1450-1457.DOI:10.1136/gutjnl-2018-317124. [49]朱慧蓉,刘天威.上海市某社区全科门诊接诊患者结直肠癌筛查认知现状的调查[J].中国全科医学,2017,20(S2):270-273. ZHU H R,LIU T W.A survey on knowledge of screening for colorectal cancer among outpatients in community of Shanghai[J].Chinese General Practice,2017,20(S2):270-273. [50]PILONIS N D,BUGAJSKI M,WIESZCZY P,et al.Participation in competing strategies for colorectal cancer screening:a randomized health services study (PICCOLINO study)[J].Gastroenterology,2021,160(4):1097-1105.DOI:10.1053/j.gastro.2020.11.049. [51]安锦慧,孙治平,李云涛,等.我国结直肠癌筛查的影响因素文献分析及思考[J].中国全科医学,2020,23(23):2877-2882.DOI:10.12114/j.issn.1007-9572.2020.00.160. AN J H,SUN Z P,LI Y T,et al.Literature review and consideration of factors influencing colorectal cancer screening in China[J].Chinese General Practice,2020,23(23):2877-2882.DOI:10.12114/j.issn.1007-9572.2020.00.160. [52]DE BEKKER-GROB E W,DONKERS B,VELDWIJK J,et al.What factors influence non-participation most in colorectal cancer screening? A discrete choice experiment[J].Patient,2021,14(2):269-281.DOI:10.1007/s40271-020-00477-w. [53]ZHANG J G,XU H F,ZHENG L Y,et al.Determinants of participation and detection rate of colorectal cancer from a population-based screening program in China[J].Front Oncol,2020,10:1173.DOI:10.3389/fonc.2020.01173. [54]DHARNI N,ARMSTRONG D,CHUNG-FAYE G,et al.Factors influencing participation in colorectal cancer screening——a qualitative study in an ethnic and socio-economically diverse inner city population[J].Health Expect,2017,20(4):608-617.DOI:10.1111/hex.12489. [55]MEESTER R G,DOUBENI C A,ZAUBER A G,et al.Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018[J].Cancer,2015,121(13):2281-2285.DOI:10.1002/cncr.29336. [56]HEAVENER T,MCSTAY F W,JAEGER V,et al.Assessing adherence and cost-benefit of colorectal cancer screening for accountable providers[J].Proc (Bayl Univ Med Cent),2019,32(4):490-497.DOI:10.1080/08998280.2019.1647702. |
| [1] | CHEN Xinyi, HUANG Ziqian, CHEN Yufeng, HUANG Jun, WENG Fan, LAI Zhisheng, XUE Yumei, CAO Xi. Diagnostic Performance of a Hand-held Single-lead ECG Device in Detecting Atrial Fibrillation and Its Potential in Atrial Fibrillation Screening in Community [J]. Chinese General Practice, 2026, 29(19): 2717-2723. |
| [2] | FAN Meixiang, YAN Yunyun, HUANG Yanyan. Interpretation and Discussion of Guidelines for Preventive Activities in General Practice: Bladder Cancer [J]. Chinese General Practice, 2026, 29(18): 2450-2453. |
| [3] | HE Zhiguang, QIU Shanjiao, CHEN Zhang, LI Anchun, HUANG Wenjing. Interpretation and Discussion of the RACGP Guidelines for Preventive Activities in General Practice: Screening for Weight Issues and Preventive Strategies [J]. Chinese General Practice, 2026, 29(12): 1505-1510. |
| [4] | Chinese Geriatrics Society, National Clinical Research Center for Geriatric Diseases (Xuanwu Hospital). Chinese Expert Consensus on Screening and Comprehensive Assessment of Intrinsic Capacity in Older Adults [J]. Chinese General Practice, 2026, 29(10): 1225-1238. |
| [5] | QIU Shanjiao, CHEN Zhang, LI Anchun, HE Zhiguang, HUANG Wenjing. Screening and Case Finding for Coeliac Disease: Lessons for Chinese General Practice from the RACGP Guidelines of Preventive Activities [J]. Chinese General Practice, 2026, 29(10): 1246-1249. |
| [6] | WANG Chenyu, WANG Xiaoyan, ZHANG Lixiu, WANG Lina. Advances in Community Screening and Diagnostic Management Strategies for Individuals with Mild Cognitive Impairment [J]. Chinese General Practice, 2026, 29(08): 1037-1043. |
| [7] | PANG Ting, LI Wanxin, ZHANG Haoran, LIN Zhiying, XU Xin. Construction of the Evaluation System of Cognitive Impairment Screening Service in the Community Based on RE-AIM Framework [J]. Chinese General Practice, 2026, 29(08): 1044-1050. |
| [8] | YU Hao, LIAO Peng, LUO Li. Digital Therapy for Stroke: Progress and Challenges from Screening to Intervention [J]. Chinese General Practice, 2026, 29(02): 240-246. |
| [9] | Cardiovascular Internal Medicine Professional Committee of China Medical Education Association, Cardiovascular Health Medicine Branch of China International Exchange and Promotion Association for Medical Care. Expert Consensus on Early Screening and Prevention of Coronary Artery Disease in Young People [J]. Chinese General Practice, 2026, 29(02): 137-147. |
| [10] | WU Hui, WANG Luya, LI Jialu, ZHANG Jun. Key Points Interpretation of Chinese Expert Consensus on Early Screening and Management of Homozygous Familial Hypercholesterolemia (2024) [J]. Chinese General Practice, 2025, 28(36): 4535-4540. |
| [11] | China Rehabilitation Science Institute, Community-Based Rehabilitation Committee of the China Association of Rehabilitation of Disabled Persons, Geriatric Rehabilitation Committee of Chinese Association of Geriatric Research, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) /Southern Medical University, Guangzhou Association of Rehabilitation Medicine. Expert Consensus on Sarcopenia Screening in Community-dwelling Older Adults [J]. Chinese General Practice, 2025, 28(36): 4517-4534. |
| [12] | ZHANG Hui, LUO Miaomiao, YU Xiaohang, LIN Xin, YE Lina, TANG Xuan, LI Jiaxue, XIE Xinyu, LAI Li, FENG Yan, LIU Yonghui, CHEN Weigang. The Application Value of a Novel Cell Collector for the Esophagus in Screening for Esophageal Lesions [J]. Chinese General Practice, 2025, 28(35): 4487-4493. |
| [13] | Community Rehabilitation Working Committee of Chinese Rehabilitation Medicine Association. Chinese Expert Consensus on Constipation Screening and Assessment for Community Cancer Patients (2025 Edition) [J]. Chinese General Practice, 2025, 28(34): 4249-4257. |
| [14] | ZHANG Lei, ZHANG Huanyu, CHEN Kaiyue, LI Xiaohong, GUO Ying. Research on the Screening Effect and Strategy of Fasting Plasma Glucose and Glycosylated Hemoglobin for Type 2 Diabetes and Prediabetes Mellitus [J]. Chinese General Practice, 2025, 28(32): 4055-4061. |
| [15] | ZHANG Jia, WANG Hairong, ZHAO Jing, SU Yifan. Influencing Factors of Screening Behavior of First-degree Relatives of Lung Cancer Patients Based on Logistic Regression and Decision Tree Model [J]. Chinese General Practice, 2025, 28(31): 3961-3967. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||